"The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of dalbavancin 500 mg (Xydalba, Durata Therapeutics) for acute bacterial skin and skin structure infections (ABSSSI) in ad"...
Luzu Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Luzu (luliconazole) Cream, 1% is an azole antifungal agent used indicated to topically treat interdigital tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm of the body) caused by the organisms Trichophyton rubrum and Epidermophyton floccosum. Common side effects of Luzu Cream include application site reactions such as skin irritation (contact dermatitis) or infection (cellulitis).
Apply a thin layer of Luzu Cream, 1% to the affected area and approximately 1 inch of the immediate surrounding area(s) once daily for one (1) to two (2) weeks, depending on the organism being treated. Luzu may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Luzu Cream should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Luzu (luliconazole) Cream, 1% Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Luzu FDA Prescribing Information: Side Effects
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in practice.
In three Phase 3 clinical trials, 616 subjects were exposed to LUZU Cream, 1%: 305 with interdigital tinea pedis and 311 subjects with tinea cruris. Subjects with interdigital tinea pedis or tinea cruris applied LUZU Cream, 1% or vehicle cream once daily for 14 days or 7 days, respectively, to affected and adjacent areas. During clinical trials with LUZU Cream, 1% the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the LUZU and vehicle arms. Most adverse reactions were mild in severity.
The following adverse reactions have been identified during postmarketing use of luliconazole cream, 1%: contact dermatitis and cellulitis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Read the entire FDA prescribing information for Luzu (Luliconazole Cream, 1%)
Additional Luzu Information
Report Problems to the Food and Drug Administration
Find out what women really need.